Microbix Biosystems Inc. (MBX.TO)
CAD 0.36
(-5.26%)
CAD 0.36
(-5.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 10.21 Million CAD | 20.0% |
| 2022 | 8.51 Million CAD | 37.17% |
| 2021 | 6.2 Million CAD | 19.71% |
| 2020 | 5.18 Million CAD | -4.64% |
| 2019 | 5.43 Million CAD | 3.37% |
| 2018 | 5.26 Million CAD | -2.36% |
| 2017 | 5.38 Million CAD | 30.1% |
| 2016 | 4.14 Million CAD | -12.79% |
| 2015 | 4.74 Million CAD | 48.62% |
| 2014 | 3.19 Million CAD | 3.47% |
| 2013 | 3.08 Million CAD | -28.71% |
| 2012 | 4.33 Million CAD | -6.37% |
| 2011 | 4.62 Million CAD | -14.1% |
| 2010 | 5.38 Million CAD | -9.24% |
| 2009 | 5.93 Million CAD | -1.18% |
| 2008 | 6 Million CAD | 40.49% |
| 2007 | 4.27 Million CAD | 12.16% |
| 2006 | 3.81 Million CAD | 49.42% |
| 2005 | 2.55 Million CAD | -3.02% |
| 2004 | 2.62 Million CAD | 16.93% |
| 2003 | 2.24 Million CAD | 20.6% |
| 2002 | 1.86 Million CAD | 8.08% |
| 2001 | 1.72 Million CAD | 3.15% |
| 2000 | 1.67 Million CAD | -70.13% |
| 1999 | 5.6 Million CAD | 24.44% |
| 1998 | 4.5 Million CAD | 95.65% |
| 1997 | 2.3 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 3.65 Million CAD | 51.19% |
| 2024 Q2 | 2.51 Million CAD | -31.23% |
| 2024 Q3 | 2.58 Million CAD | 2.82% |
| 2023 Q3 | 3 Million CAD | 25.17% |
| 2023 Q2 | 2.4 Million CAD | 0.68% |
| 2023 Q1 | 2.38 Million CAD | 4.86% |
| 2023 FY | 10.21 Million CAD | 20.0% |
| 2023 Q4 | 2.41 Million CAD | -19.73% |
| 2022 Q2 | 2.17 Million CAD | 3.78% |
| 2022 Q1 | 2.1 Million CAD | 26.13% |
| 2022 FY | 8.51 Million CAD | 37.17% |
| 2022 Q4 | 2.27 Million CAD | 16.36% |
| 2022 Q3 | 1.95 Million CAD | -10.21% |
| 2021 Q2 | 1.53 Million CAD | 13.11% |
| 2021 FY | 6.2 Million CAD | 19.71% |
| 2021 Q3 | 1.65 Million CAD | 8.15% |
| 2021 Q4 | 1.66 Million CAD | 0.53% |
| 2021 Q1 | 1.35 Million CAD | 32.35% |
| 2020 Q3 | 1.53 Million CAD | 21.07% |
| 2020 Q4 | 1.02 Million CAD | -33.53% |
| 2020 FY | 5.18 Million CAD | -4.64% |
| 2020 Q1 | 1.35 Million CAD | -5.77% |
| 2020 Q2 | 1.27 Million CAD | -6.25% |
| 2019 Q1 | 1.15 Million CAD | -21.22% |
| 2019 Q2 | 1.4 Million CAD | 22.23% |
| 2019 FY | 5.43 Million CAD | 3.37% |
| 2019 Q4 | 1.43 Million CAD | -0.08% |
| 2019 Q3 | 1.44 Million CAD | 2.36% |
| 2018 Q3 | 1.3 Million CAD | 1.46% |
| 2018 Q2 | 1.28 Million CAD | 7.03% |
| 2018 Q1 | 1.2 Million CAD | -31.24% |
| 2018 Q4 | 1.46 Million CAD | 11.8% |
| 2018 FY | 5.26 Million CAD | -2.36% |
| 2017 FY | 5.38 Million CAD | 30.1% |
| 2017 Q1 | 1.12 Million CAD | -22.43% |
| 2017 Q4 | 1.75 Million CAD | 22.24% |
| 2017 Q3 | 1.43 Million CAD | 32.2% |
| 2017 Q2 | 1.08 Million CAD | -3.36% |
| 2016 Q4 | 1.44 Million CAD | 29.73% |
| 2016 FY | 4.14 Million CAD | -12.79% |
| 2016 Q1 | 606.24 Thousand CAD | -66.73% |
| 2016 Q2 | 975.49 Thousand CAD | 60.91% |
| 2016 Q3 | 1.11 Million CAD | 14.2% |
| 2015 Q2 | 1.11 Million CAD | 28.08% |
| 2015 Q1 | 871.85 Thousand CAD | -27.17% |
| 2015 Q4 | 1.82 Million CAD | 94.31% |
| 2015 Q3 | 937.65 Thousand CAD | -16.03% |
| 2015 FY | 4.74 Million CAD | 48.62% |
| 2014 Q3 | 633.11 Thousand CAD | -2.73% |
| 2014 FY | 3.19 Million CAD | 3.47% |
| 2014 Q4 | 1.19 Million CAD | 89.08% |
| 2014 Q2 | 650.86 Thousand CAD | -8.81% |
| 2014 Q1 | 713.7 Thousand CAD | 10.38% |
| 2013 Q4 | 646.57 Thousand CAD | -14.94% |
| 2013 Q2 | 739.25 Thousand CAD | -14.35% |
| 2013 Q1 | 863.06 Thousand CAD | 19.17% |
| 2013 Q3 | 760.14 Thousand CAD | 2.82% |
| 2013 FY | 3.08 Million CAD | -28.71% |
| 2012 FY | 4.33 Million CAD | -6.37% |
| 2012 Q3 | 1.24 Million CAD | -4.82% |
| 2012 Q2 | 1.31 Million CAD | 43.83% |
| 2012 Q1 | 912.44 Thousand CAD | -12.21% |
| 2012 Q4 | 724.26 Thousand CAD | -42.02% |
| 2011 Q4 | 1.03 Million CAD | -15.25% |
| 2011 Q2 | 1.32 Million CAD | 41.51% |
| 2011 Q1 | 935.87 Thousand CAD | -9.68% |
| 2011 Q3 | 1.22 Million CAD | -7.4% |
| 2011 FY | 4.62 Million CAD | -14.1% |
| 2010 Q2 | 1.46 Million CAD | 18.88% |
| 2010 Q4 | 1.03 Million CAD | -37.45% |
| 2010 FY | 5.38 Million CAD | -9.24% |
| 2010 Q1 | 1.23 Million CAD | -34.35% |
| 2010 Q3 | 1.65 Million CAD | 13.27% |
| 2009 Q3 | 1.18 Million CAD | -23.87% |
| 2009 Q2 | 1.55 Million CAD | 14.55% |
| 2009 Q1 | 1.35 Million CAD | 20.86% |
| 2009 FY | 5.93 Million CAD | -1.18% |
| 2009 Q4 | 1.87 Million CAD | 58.59% |
| 2008 Q3 | 1.7 Million CAD | -4.9% |
| 2008 Q4 | 1.12 Million CAD | -34.4% |
| 2008 Q2 | 1.79 Million CAD | 24.95% |
| 2008 Q1 | 1.43 Million CAD | 35.33% |
| 2008 FY | 6 Million CAD | 40.49% |
| 2007 Q4 | 1.06 Million CAD | -25.1% |
| 2007 Q3 | 1.41 Million CAD | 37.89% |
| 2007 Q2 | 1.02 Million CAD | 34.76% |
| 2007 Q1 | 763.56 Thousand CAD | -48.47% |
| 2007 FY | 4.27 Million CAD | 12.16% |
| 2006 Q4 | 1.48 Million CAD | 113.86% |
| 2006 Q3 | 692.93 Thousand CAD | -19.36% |
| 2006 Q2 | 859.25 Thousand CAD | 10.63% |
| 2006 FY | 3.81 Million CAD | 49.42% |
| 2006 Q1 | 776.65 Thousand CAD | 37.75% |
| 2005 Q2 | 499.21 Thousand CAD | -32.84% |
| 2005 FY | 2.55 Million CAD | -3.02% |
| 2005 Q1 | 743.34 Thousand CAD | -0.52% |
| 2005 Q4 | 563.79 Thousand CAD | -24.23% |
| 2005 Q3 | 744.06 Thousand CAD | 49.05% |
| 2004 FY | 2.62 Million CAD | 16.93% |
| 2004 Q2 | 546.12 Thousand CAD | -13.99% |
| 2004 Q3 | 701.63 Thousand CAD | 28.48% |
| 2004 Q4 | 747.2 Thousand CAD | 6.49% |
| 2004 Q1 | 634.91 Thousand CAD | -15.19% |
| 2003 Q3 | 418.99 Thousand CAD | -20.85% |
| 2003 Q2 | 529.33 Thousand CAD | -4.13% |
| 2003 Q1 | 552.14 Thousand CAD | 52.68% |
| 2003 FY | 2.24 Million CAD | 20.6% |
| 2003 Q4 | 748.65 Thousand CAD | 78.68% |
| 2002 Q2 | 489.07 Thousand CAD | 8.32% |
| 2002 Q4 | 361.63 Thousand CAD | -35.74% |
| 2002 Q3 | 562.75 Thousand CAD | 15.07% |
| 2002 FY | 1.86 Million CAD | 8.08% |
| 2002 Q1 | 451.51 Thousand CAD | 11.88% |
| 2001 Q4 | 403.55 Thousand CAD | -5.33% |
| 2001 Q3 | 426.28 Thousand CAD | 0.98% |
| 2001 Q2 | 422.15 Thousand CAD | -10.87% |
| 2001 Q1 | 473.63 Thousand CAD | 27.01% |
| 2001 FY | 1.72 Million CAD | 3.15% |
| 2000 FY | 1.67 Million CAD | -70.13% |
| 2000 Q4 | 372.9 Thousand CAD | -6.77% |
| 2000 Q3 | 400 Thousand CAD | -33.33% |
| 2000 Q2 | 600 Thousand CAD | 100.0% |
| 2000 Q1 | 300 Thousand CAD | -91.67% |
| 1999 Q2 | 700 Thousand CAD | 0.0% |
| 1999 Q3 | 600 Thousand CAD | -14.29% |
| 1999 Q1 | 700 Thousand CAD | 800.0% |
| 1999 Q4 | 3.6 Million CAD | 500.0% |
| 1999 FY | 5.6 Million CAD | 24.44% |
| 1998 Q4 | -100 Thousand CAD | -106.25% |
| 1998 Q3 | 1.6 Million CAD | -15.79% |
| 1998 Q2 | 1.9 Million CAD | 90.0% |
| 1998 FY | 4.5 Million CAD | 95.65% |
| 1998 Q1 | 1 Million CAD | 42.86% |
| 1997 Q1 | 500 Thousand CAD | 0.0% |
| 1997 Q4 | 700 Thousand CAD | 16.67% |
| 1997 Q3 | 600 Thousand CAD | 20.0% |
| 1997 Q2 | 500 Thousand CAD | 0.0% |
| 1997 FY | 2.3 Million CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.83 Million CAD | -15.626% |
| Eupraxia Pharmaceuticals Inc. | 37.92 Million CAD | 73.057% |
| Helix BioPharma Corp. | 9.35 Million CAD | -9.199% |
| Medicenna Therapeutics Corp. | 19.66 Million CAD | 48.036% |
| Satellos Bioscience Inc. | 6.64 Million CAD | -53.743% |
| Oncolytics Biotech Inc. | 33.79 Million CAD | 69.762% |
| Sernova Corp. | 41.13 Million CAD | 75.158% |